New shot for stubborn constipation pain enters Mid-Stage trial
NCT ID NCT07545772
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an injected drug called brenipatide in 342 adults with irritable bowel syndrome with constipation (IBS-C). Participants will receive either the drug or a placebo for about 35 weeks. The goal is to see if brenipatide safely reduces abdominal pain and improves bowel habits better than a dummy shot.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brenipatide (a drug injected under the skin)
What this could lead to
If it works, this could lead to a new treatment option that eases abdominal pain and improves bowel movements for people with IBS-C.
What could go wrong
This is an early Phase 2 trial, so the drug may not prove more effective than placebo. Side effects are still being studied, and results may not apply to all IBS-C patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONSTIPATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gastroenterology Health Partners Loc. 1
RECRUITINGLouisville, Kentucky, 40218, United States
Contact Phone: •••-•••-••••